- Latest available (Revised)
- Original (As made)
This is the original version (as it was originally made). This item of legislation is currently only available in its original format.
7. In the table in Schedule 3A to the POM Order(1), (substances which may be prescribed, administered or directed for administration by extended formulary nurse prescribers)—
(a)in column 1 insert, at the appropriate place in the alphabetical order of the entries as they appear in that column, the entry set out in column 1 below, and in column 2, insert, against that entry, the corresponding entry in column 2 below—
Column 1 | Column 2 |
---|---|
Acetylcysteine | Parenteral |
Adrenaline | Parenteral |
Alteplase | Parenteral |
Amiodarone | Parenteral |
Bemiparin sodium | Parenteral |
Benzatropine mesilate | Parenteral |
Calcipotriol | External |
Calcitriol | External |
Cefotaxime sodium | Parenteral |
Ceftriaxone Sodium | Parenteral |
Certoparin sodium | Parenteral |
Chlorphenamine maleate | Parenteral |
Cimetidine | Parenteral |
Cyclizine hydrochloride | Oral |
Cyclizine lactate | Parenteral |
Dalteparin sodicum | Parenteral |
Dexamethasone sodium phosphate | Oral |
Dextran 70 | Parenteral |
Dolesetron mesilate | Oral and parenteral |
Enoxaparin | Parenteral |
Furosemide | Oral and parenteral |
Gelatin 3.5 – 4% | Parenteral |
Glucose 5% | Parenteral |
Glucose 5% with Potassium (K+ 40 mmol/L) ready made infusion bag | Parenteral |
Granisetron hydrochloride | Parenteral |
Heparin sodium | Parenteral for the purpose of cannulae flushing |
Hexastarch | Parenteral |
Human soluble insulin | Parenteral |
Hydroxyethl starch | Parenteral |
Levomepromazine | Oral and parenteral |
Naloxone | Parenteral |
Omeprazole | Oral |
Omeprazole sodium | Parenteral |
Ondansetron Hydrochloride | Oral and parenteral |
Oxbuprocaine hydrochloride | Ophalmic |
Pentastarch | Parenteral |
Prilocaine | External and parenteral |
Prochlorperazine mesilate | Oral and rectal |
Prochlorperazine maleate | Oral, rectal and buccal |
Proxymetacaine hydrochloride | Ophthalmic |
Reteplase | Parenteral |
Sodium chloride 0.9% | Parental, for reconstitution of injections and for the purpose of cannulae flushing |
Sodium chloride 0.9% & Glucose 5% ready made infusion bag | Parenteral |
Sodium chloride 0.45% & Glucose 5% ready made infusion bag | Parenteral |
Sodium chloride 0.9% with Potassium (K+ 40 mmol/L) ready made infusion bag | Parenteral |
Sodium chloride 0.45% and Glucose 5% with Potassium 20mmol per 500 ml ready made infusion bag | Parenteral |
Streptokinase | Parenteral |
Tacalcitol | External |
Tenecteplase | Parenteral |
Tetanus immunoglobulin | Parenteral |
Tetracaine | External |
Tinzaparin sodium | Parenteral |
Tropicamide | Ophthalmic |
Tropisetron hydrochloride | Parenteral |
Unfractionated Heparin | Parenteral |
Vaccine – Combined Tetanus, diphtheria, acullular pertussis, inactivated poliomyelitis and haemophilus influenza type B | Parenteral |
Vaccine – Inactivated Poliomyelitis | Parenteral |
Vaccine – Meningococcal Polysaccharide A, C, W135 and Y | Parenteral |
(b)in the entry for “Beclometasone dipropionate”, in column 2, after “nasal” add “inhalation”;
(c)in the entry for “Budesonide”, in column 2, after “Nasal” add “inhalation”;
(d)omit the entry for “Cyclizine”;
(e)in the entry for “Diazepam”(2), in column 2, omit “in palliative care”;
(f)in the entry for “Diclofenac sodium”(3), in column 2, after “oral” omit “or” and after “rectal” add “or ophthalmic”;
(g)in the entry for “Domperidone”, in column 2, omit “in palliative care”;
(h)in the entry for “Domperidone maleate”, in column 2, omit “in palliative care”;
(i)in the entry for “Flucloxacillin sodium”, in column 2, after “oral” add “or parenteral”;
(j)in the entry for “Hydrocortisone sodium succinate”, in column 2, after “lozenges” add “or parenteral”;
(k)in the entry for “Ipratropium bromide”, in column 2, after “nasal” add “inhalation”;
(l)in the entry for “Lorazepam”(4), in column 2, omit “in palliative care”;
(m)in the entry for “metoclopramide hydrochloride”, in column 2, omit “in palliative care”;
(n)in the entry for “Midazolam”(5), in column 2, omit “in palliative care”;
(o)in the entry for “Ranitidine hydrochloride”, in column 2, after “Oral” insert “or parenteral”.
Schedule 3A was inserted by S.I. 2002/549, and amended by S.I. 2003/696 and 2915, and 2004/2, 1189 and 2693.
The entry for “Diazepam” was inserted by S.I. 2003/2915.
The entry for “Diclofenac Sodium” was inserted by S.I. 2004/2.
The entry for “Lorazepam” was inserted by S.I. 2003/2915.
The entry for “Midazolam” was inserted by S.I. 2003/2915.
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: